> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 7 Observations in Natco Pharma FDA-483
- URL: https://www.fdaweb.com/7-observations-in-natco-pharma-fda-483/
- Published: 2025-07-16T12:00:00.000Z
- Updated: 2026-09-14T15:16:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159515

FDA has released the form FDA-483 issued following a 6/9-6/19 inspection at Natco Pharma Limited, a Rangareddy, Telangana, India, sterile and non-sterile drug manufacturer. The seven inspection observations were:

- aseptic processing areas are deficient regarding the system for monitoring environmental conditions;
- failure to maintain equipment and utensils at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality, or purity of the drug product;
- procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process;
- failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- failure to establish, write, and follow procedures designed to prevent microbiological contamination of drug products purporting to be sterile;
- buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operation; and
- failure to have in writing and fully follow the responsibilities and procedures applicable to the quality control unit.